XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2017
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Jan. 14, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Adjustments to transaction price for performance obligations   $ 0 $ 0    
Research and development   3,103,000 4,204,000    
Collaborative Arrangements [Member] | Phase 2 MRCT [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Maximum contribution amount to clinical trial   3,000,000      
Collaborative Arrangements [Member] | Reneo [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Collaboration revenue recognized   0 0    
Collaborative Arrangements [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Adjustments to transaction price for performance obligations   0      
Collaborative Arrangements [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] | Phase 2 MRCT [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Maximum contribution amount to clinical trial         $ 3,000,000
Unrecognized amount of transaction price allocated to performance obligation   1,000,000      
Collaborative Arrangements [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] | Phase 2 MRCT [Member] | License and Technology Transfer Services of Chemistry and Manufacturing Know-How [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Collaboration revenue recognized     $ 0    
Adjustments to transaction price for performance obligations   1,000,000      
Collaborative Arrangements [Member] | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. [Member] | Joint Development Committee [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Unrecognized amount of transaction price allocated to performance obligation   100,000      
Collaborative Arrangements [Member] | Newsoara Biopharma Co Ltd [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Revenue recognized from change in estimated transaction prices   0      
Collaborative Arrangements [Member] | Newsoara Biopharma Co Ltd [Member] | License And Technology Transfer Services [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Collaboration revenue recognized   0      
Collaborative Arrangements [Member] | Anteris Bio, Inc. [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
License fee received       $ 2,000,000  
Potential development and regulatory milestone payments       151,000,000  
Collaborative Arrangements [Member] | Anteris Bio, Inc. [Member] | License and Technology Transfer Services of Chemistry and Manufacturing Know-How [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
License fee received       2,000,000  
Equity interest received       $ 4,200,000  
Collaborative Arrangements [Member] | JDRF [Member]          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Maximum research funding receivable achievement based on research and development milestones $ 3,000,000        
Maximum funding percentage of research and development milestones 50.00%        
Funding received   3,000,000      
Research and development   $ 3,000,000